

Draft January 17, 2025

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

February 26-28, 2025

Wednesday, February 26, 2025

8:00 Welcome & Introductions

Dr. Keipp Talbot (ACIP Chair)

Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

8:30 Meningococcal Vaccines

Introduction

Dr. Jamie Loehr (ACIP, WG Chair)

GSK Pentavalent Vaccine: Review of EtR and Work Group Considerations

Dr. Sarah Schillie (CDC/NCIRD)

Updates to Meningococcal Vaccines VFC Resolution

Dr. Jeanne Santoli (CDC/NCIRD)

Introduction to MenQuadfi Label Change for Infants

Dr. Sarah Schillie (CDC/NCIRD)

MenQuadfi in Infants: Safety and Immunogenicity

Dr. Rachel Dawson (Sanofi)

Work Group Considerations regarding MenQuadfi in Infants

Dr. Sarah Schillie (CDC/NCIRD)

9:45

Break

10:00 Chikungunya Vaccines

Introduction

Dr. Edwin Asturias (ACIP/WG Chair)

Surveillance for adverse events following use of live attenuated chikungunya vaccine and its use among travelers

Dr. Susan Hills (CDC/NCEZID) and TBD

EtR for use of virus-like particle chikungunya vaccine among adolescent and adult travelers

Dr. Susan Hills (CDC/NCEZID)

EtR for use of virus-like particle chikungunya vaccine among laboratory workers

Dr. Susan Hills (CDC/NCEZID)

Clinical guidance for use of virus-like particle chikungunya vaccine among pregnant and breastfeeding individuals

Dr. Susan Hills (CDC/NCEZID) and TBD

12:30

Break

1:10 Influenza Vaccines

Introduction

Dr. Jamie Loehr (ACIP, WG Chair)

Influenza Vaccine Effectiveness Update

TBD

FluMist Self or Caregiver Administration

TBD

LAIV for people with asthma

TBD

Influenza Vaccines VFC Resolution

Dr. Jeanne Santoli (CDC/NCIRD)

3:10

Break

3:20 Public Comment

3:40 VOTES

Meningococcal Vaccines

Dr. Sarah Schillie (CDC/NCIRD)

Meningococcal Vaccines VFC

Dr. Jeanne Santoli (CDC/NCIRD)

Chikungunya Vaccines

Dr. Susan Hills (CDC/NCEZID)

Influenza Vaccines

Dr. Lisa Grohskopf (CDC/NCIRD)

Influenza Vaccines VFC

Dr. Jeanne Santoli (CDC/NCIRD)

4:10

Break

4:20 Respiratory Syncytial Virus (RSV) Vaccines - Maternal/Pediatric

Introduction

Dr. Helen Chu (ACIP, WG Chair)

Evidence to Recommendations: Clesrovimab

Ms. Danielle Moulia (CDC/NCIRD)

Clinical Considerations

Dr. Jefferson Jones (CDC/NCIRD)

5:20 Recess

Thursday, February 27, 2025

8:00 Welcome & Introductions

Dr. Keipp Talbot (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
(CDC, CMS, FDA, HRSA, IHS, OIDP, NIH)

8:10 Agency Updates

8:30 Respiratory Syncytial Virus (RSV) Vaccines - Adults

Introduction

Dr. Albert Shaw (ACIP, WG Chair)

Manufacturer presentation: mRNA-1345 (Moderna) immunogenicity in adults 18-59 at increased risk; 24-month re-vaccination

TBD (Moderna)

Manufacturer presentation: Arexvy (GSK) immunogenicity in adults 18-49 at increased risk; 36-month re-vaccination

TBD (GSK)

Post marketing surveillance: FDA

TBD (FDA)

Economic analysis of adult RSV vaccination

Dr. David Hutton (University of Michigan)

Update to benefits and risk discussion

Dr. David Hutton (University of Michigan)

Comparison of economic analyses of adult RSV vaccination

Dr. Ismael Ortega-Sanchez (CDC/NCIRD)

Evidence to Recommendations

TBD (CDC/NCIRD)

Clinical Considerations

TBD (CDC/NCIRD)

11:30

Break

11:40 Public Comment

12:00 VOTES

RSV Vaccines - Adults

TBD (CDC/NCIRD)

12:25

Break

12:55 Human Papillomavirus (HPV) Vaccines

Introduction

Dr. Oliver Brooks (ACIP, WG Chair)

Update on literature related to reduced number of doses for HPV vaccination series

Dr. Carla DeSisto (CDC/NCIRD)

KEN SHE study

Dr. Ruanne Barnabas (Harvard University)

Modeling of reduced number of doses for HPV vaccination series

TBD

Modified EtR: Wording of the age for routine HPV vaccination

Dr. Ruth Stefanos (CDC/NCIRD)

Work Group next steps

Dr. Lauri Markowitz (CDC/NCIRD)

2:55

Break

3:10 Mpox Vaccine

Introduction

Dr. Bonnie Maldonado (ACIP, WG Chair)

Presentation on immunogenicity and safety of JYNNEOS in 12-17 year olds

Dr. Buddy Creech (Vanderbilt)

EtR for JYNNEOS in outbreaks and due to the 2022 global outbreak

Dr. Faisal Minhaj (CDC/NCEZID)

4:50 Pneumococcal Vaccines

Workgroup Next Steps and Proposed Work Plan

Dr. Miwako Kobayashi (CDC/NCIRD)

5:05 Lyme Disease Workgroup

Dr. Grace Marx (CDC/NCEZID)

5:10 Recess

Friday, February 28, 2025

8:00 Welcome & Introductions

Dr. Keipp Talbot (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

8:10 COVID-19 Vaccines

Introduction
Moderna mRNA-1283 COVID-19 vaccine
Epidemiology and risk factors for COVID-19 hospitalizations
Vaccine effectiveness update
Work Group Considerations for use of 2025-2026 COVID-19 vaccines

Dr. Robert Schechter (ACIP, WG Chair)
TBD (Moderna)
Dr. Fiona Havers (CDC/NCIRD)
Dr. Ruth Link-Gelles (CDC/NCIRD)
TBD (CDC/NCIRD)

10:10 Break

10:25 Cytomegalovirus (CMV) Vaccines

Introduction
CMV and cCMV epidemiology and disease burden
CMV vaccine safety and immunogenicity data
Initial work group considerations for CMV vaccine policy

Dr. Denise Jamieson (ACIP, WG Chair)
Dr. Tatiana Lanzieri (CDC/NCIRD)
Dr. Lori Panther (Moderna)
Dr. Tatiana Lanzieri (CDC/NCIRD)

11:25 Adjourn

Acronyms

CDC Centers for Disease Control and Prevention
CMS Centers for Medicare and Medicaid Services
CORVD Coronavirus and Other Respiratory Viruses Division
COVID-19 Coronavirus disease 2019
EtR Evidence to Recommendations Framework
FDA Food and Drug Administration
GRADE Grading of Recommendations Assessment, Development and Evaluation
HRSA Health Resources and Services Administration
HPV Human papillomavirus
IHS Indian Health Service
ISO Immunization Safety Office
NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention
NCIRD National Center for Immunization & Respiratory Diseases
NCEZID National Center for Emerging and Zoonotic Diseases
NIAID National Institute of Allergy and Infectious Diseases
OIDP Office of Infectious Disease and HIV/AIDS Policy
RSV Respiratory Syncytial Virus (RSV)
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2
WG Work Group
WHO World Health Organization
VAERS Vaccine Adverse Event Reporting System
VE Vaccine Effectiveness
VFC Vaccines for Children